Nestlé's $523M yfood Bet and Danone's Huel Deal: Why Big Food Is Racing Into GLP-1-Era Nutrition

Two of the world's biggest food companies made near-identical bets on meal replacement brands within three months of each other. That is not a coincidence.

On June 3, Nestlé confirmed the acquisition of the remaining 51% of yfood Labs, the European ready-to-drink meal brand it partially acquired in 2023. The deal values yfood at approximately $523 million. Three months earlier, Danone spent a reported $1.2 billion on Huel, the UK-based high-protein meal replacement company. Both deals target the same consumer trend. Both were executed under new CEOs running portfolio resets. And both point to the same underlying force reshaping food M&A: GLP-1 medications.

A $523 Million Signal

yfood is not a household name outside of Europe. But the numbers are compelling. The brand generated $174 million (EUR 150 million) in net sales in 2025, a double-digit increase from the prior year. It sells across 30 countries through more than 50,000 points of sale. Nestlé initially took a 49% minority stake in 2023 to test the model. The decision to buy the remainder is a vote of confidence in the category and in the brand's ability to scale under a multinational's distribution infrastructure.

This is also CEO Philipp Navratil's first acquisition since taking the Nestlé top job. Navratil has been executing a portfolio overhaul — exiting Blue Bottle Coffee, progressing a Froneri ice cream exit, and preparing the waters division for a strategic review. His stated four pillars are coffee, petcare, nutrition, and food and snacks. yfood lands squarely in nutrition, alongside existing brands Boost and Vital collagen. Acquiring the full business, rather than holding a minority stake, signals that Navratil wants control of the category rather than a passive financial position.

GLP-1 Is the Real Driver

The deeper story is not about meal replacement as a category in isolation. It is about what GLP-1 drugs are doing to the food industry at a structural level.

Medications such as Ozempic and Wegovy suppress appetite. Users consume fewer calories. But they still need adequate protein, vitamins, and micronutrients — in smaller, more frequent portions, and from formats that are easy to consume and digest. The ideal product for a GLP-1 user is nutrient-dense, portion-controlled, portable, and convenient. That is a near-perfect description of yfood and Huel.

Analysts estimate 30 to 40 million Americans are on GLP-1 medications today or will be within five years. The impact on total calorie volumes is already showing up in snack data. PepsiCo, Hershey, and General Mills have all flagged GLP-1-related volume softness in their 2025 and Q1 2026 earnings calls. The companies buying into meal replacement are not just acquiring growth brands. They are hedging against the structural erosion of their legacy snack and confectionery volumes — and building a position in the category most likely to grow as GLP-1 adoption accelerates.

Why This Race Matters

What is striking about these two deals is the speed and the scale. Nestlé and Danone are not testing the water. They are paying premium multiples — yfood was valued at roughly 3x its 2025 annual sales — for assets built entirely outside the traditional food system. yfood and Huel were both founded by entrepreneurs with no legacy factory infrastructure, no grocery trade dependency, and no Big Food playbook. They grew through e-commerce, fitness culture, and direct-to-consumer channels before landing in mainstream supermarkets.

That origin matters because it tells you something about where consumer trust is now going. A meal replacement brand built by a startup carries fundamentally different brand equity than a legacy supplement brand owned by a multinational's health science division. Acquiring yfood whole gives Nestlé the brand equity alongside the operational capability.

It also puts Nestlé in direct competition with Danone in a segment that barely existed a decade ago. Danone already owns Aptamil, Nutricia, and Fortisip — clinical nutrition assets primarily targeting infants and medically vulnerable patients. Huel and the yfood acquisition push both companies into everyday consumer nutrition, where GLP-1 adoption is most concentrated and where consumers are actively looking for brands that feel different from Big Food.

The Parallel Portfolio Logic

Both Nestlé and Danone are shedding complexity while converging on nutrition. Nestlé is exiting Blue Bottle, Froneri, and potentially its waters division. Danone sold Aqua and is restructuring around health nutrition and dairy. In both cases, the strategic logic converges on the same answer: everyday nutrition for health-conscious consumers is the category worth building around in the GLP-1 era.

For operators in the functional food and beverage space, the message is clear. The largest buyers in the world are prepared to pay above 3x revenue for high-growth nutrition brands. The window for independent brands in this space to build credible scale — and find a strategic exit — is wide open, but it will not stay that way.

For investors and M&A advisors, the convergence of Nestlé and Danone into the same category within 90 days is the most important signal from the first half of 2026. When two companies of this scale make near-identical portfolio moves in rapid succession, they are reading the same underlying demand data — and the rest of the industry needs to be reading it too.